Work

Interim data analysis of the ADAPT trial using the modified intent to treat (mITT) population re-evaluates Rocapuldencel-T for clinical benefit over standard of care.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.4557

Authors: Robert A. Figlin, Christopher G. Wood, Alicia H. Gamble, Ana Plachco, Marcus S. Norris, Joe M. Horvatinovich, Irina Y. Tcherepanova, Charles A. Nicolette, Mark A. DeBenedette

Institutions: Cedars-Sinai Medical Center, The University of Texas MD Anderson Cancer Center, Argos Therapeutics (United States)

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890594281

Cites:

Cited by: 1

Related to: 10